Calculate target mg/mL concentration, gross lyophilizate overfill (HPLC purity × net peptide content), and μM molarity.
CJC-1295 without DAC 5mg + Ipamorelin 5mg Co-Formulated Vial
Co-formulated vial containing CJC-1295 without DAC 5mg and Ipamorelin 5mg, for qualified B2B sourcing, with per-component batch documentation and custom fill discussion.
Review specifications, files, and next-step support before requesting samples.
- Confirm the peptide name, CAS, and core specifications
- Check typical applications and document availability
- Use one inquiry path for pricing, files, samples, or project discussion
Key Review Snapshot
Key Review Snapshot
Compare Track A (~5–7 day stock dispatch) vs. Track B (4–6 week custom runs) and 60-day sample credit.
Verify our exhibiting entity (Suzhou Xilin Technology Co., Ltd.), booth photos, and on-site COA/HPLC review.
Why buyers trust WUMO
Real content, documented — not guesswork
In peptide sourcing, chromatographic purity and delivered quantity require separate evaluation. We keep purity and labeling basis distinct on available documentation, so buyers can review analytical parameters for their quoted batch before ordering.
Purity vs quantity distinction
Purity (%) and reported quantity are distinct analytical parameters. Review purity and reported quantity separately, and confirm the labeling and assay basis for the batch proposed for your order.
Batch-specific documents
Batch documentation reflects the specific lot produced. Ask which batch-specific documents are available for the quoted lot, including COA and supporting HPLC or MS records where applicable.
Documented before commitment
Ingredient identity (INCI / CAS), specification sheet, and SDS are available for technical review. Confirm documentation for the batch proposed for your order before purchase.
Documents Available
Documents Available
COA
Batch-specific COA
Batch-level quality summary for buyer-side file review.
Request this file through the inquiry path below.
HPLC
HPLC purity report
Purity profile reference for the quoted project or batch where available.
Request this file through the inquiry path below.
MS
MS identity report
Identity confirmation support for documentation review where available.
Request this file through the inquiry path below.
SDS
SDS / MSDS
Safety document requested for internal purchasing and handling review.
Request this file through the inquiry path below.
Spec
Product specification sheet
Product or packaging specification reference for quotation alignment.
Request this file through the inquiry path below.
Overview
Overview
B2B Review Guide
B2B Review Guide
Product Overview
This is a co-formulated lyophilized vial containing two peptides: Modified GRF (1-29) — commercially listed as CJC-1295 without DAC — at 5mg, and Ipamorelin at 5mg. It is supplied for qualified B2B research sourcing projects. This page describes sourcing and analytical documentation only; it does not describe biological action, combination rationale, end-user application, or product performance.
What to check on a blended vial that you would not check on a single one
- Component-level documentation. The analytical record should distinguish the two components and state clearly how identity and purity were assessed for each. Where a component-specific RP-HPLC purity figure is given, the method needs adequate chromatographic separation to support it — a number reported without that separation does not describe either component well.
- The ratio is part of the specification. 5mg + 5mg and 10mg + 2mg are different products. The ratio belongs in the written specification and on the label, not in a verbal agreement.
- Total weight is not total peptide. Counterion content, residual moisture, and any excipient sit inside the vial weight. On a two-component vial this arithmetic is easier to get wrong, so confirm what the per-vial claim is measured against.
- Which CJC-1295. This specification is Modified GRF (1-29), the non-DAC material. Confirm it on the identity record rather than the trade name.
What WUMO Can Supply
- Co-formulated vials at the 5mg + 5mg specification as standard
- Alternative ratios and fill quantities by project
- Batch-specific COA distinguishing the two components
- Neutral-label or private-label packaging, with components and ratio stated on the label
- Single-component vials as an alternative — see Modified GRF (1-29) and Ipamorelin
- MOQ, lead time, and phased delivery planning
Quality and Documentation
A batch-specific COA is issued for the batch being supplied and states the RP-HPLC and mass-spectrometry results for that batch. Purity and peptide content are separate specifications — see what a 10mg vial actually contains for the distinction and what a per-vial claim needs behind it.
Karl Fischer water content, counter-ion form, and appearance are not part of the standard vial COA scope and are arranged per project where a buyer specification requires them. Ask for the COA of the batch being quoted, and check that the batch identifier on it matches the vial label.
Compliance Note
This page is for qualified B2B technical evaluation and business-side documentation review only. Material is supplied for research and laboratory use. It is not intended for individual purchase, consumer use, or product-use guidance, and WUMO does not provide medical guidance or outcome claims. Final use, importation, labeling, and local compliance are the buyer's responsibility.
Specification and documentation references
- Lyophilized vial sourcing guide — fill amount, packaging, MOQ and documentation.
- What a 10mg vial actually contains — peptide content, counterion, moisture and excipients.
- How peptide identity is confirmed by mass spectrometry — what an identity record can and cannot establish.
FAQ
Frequently Asked Questions
Should a blended vial have one COA or two sets of results?
One COA is fine, but it should distinguish the components and say how identity and purity were assessed for each. A single combined purity figure does not adequately describe the purity of either component.
Can a component-specific purity always be reported?
Only where the analytical method separates the two peptides well enough to support it. Ask what method was used before treating two percentages as equivalent to two single-component COAs.
Can the ratio be changed?
Yes, alternative ratios and fill quantities are set per project. Whatever is agreed should appear in the written specification and on the vial label.
What should I send to get a quotation?
Company and business type, destination market, intended business use, required documentation package, target ratio and fill quantity, vial count, packaging preference, and required timeline.
Wholesale Distribution & OEM Private Label
Sourcing CJC-1295 without DAC 5mg + Ipamorelin 5mg Co-Formulated Vial for regional distribution or your own brand?
Compare 7-day ready stock (unbranded 100% Type I neutral borosilicate vials in plain white 10-vial kits) against 4–6 week scheduled factory production with 60-day blind-test sample price credit, 20+ flip-off cap colors, standard lot-matched COA + RP-HPLC + LC-MS, and optional project-specified LAL/uniformity QC: see our Regional Distributor Program or Private-Label Vial OEM Service.
Request Pricing, Files, or Samples
Use this form for pricing, technical files, sample requests, or project discussion for this product.
Need COA, SDS/MSDS, or specifications? Choose "Technical document request" in the inquiry form or mention the file name in your message.